$BNGO News

Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript

Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est

Bionano Genomics Sees Q3 Sales $8.200M-$8.600M vs $8.575M Est

Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

Bionano Genomics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Bionano Genomics, Inc. Q1 2026 Earnings Call Summary

Bionano Genomics Inc (BNGO) Q1 2026 Earnings Call Highlights: Record Flow Cell Sales and ...

Transcript: Bionano Genomics Q1 2026 Earnings Conference Call

Bionano Reports First Quarter 2026 Results and Provides a Business Update

Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript

Transcript: Bionano Genomics Q1 2026 Earnings Conference Call

Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate

Bionano Genomics Sees Q2 Sales $7.500M-$7.800M vs $7.520M Est

Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est

Bionano Genomics Files Shelf Registration To Offer Up To $400M In Common Stock, Preferred Stock, Debt, Warrants, And Units

Bionano Announces Leadership Transition

Bionano Genomics Appoints Chairman Al Luderer Interim President, CEO, Effective Immediately